Business Wire

Loomis Sayles Chief Investment Officer Jae Park Set to Retire in 2021; Deputy Chief Investment Officer David Waldman Named Successor

20.10.2020 16:05:00 EEST | Business Wire | Press release

Share

Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Jae Park, executive vice president, member of the board of directors and chief investment officer, will retire on March 31, 2021 after 19 years with the company. David Waldman, executive vice president, member of the board of directors and deputy chief investment officer, will succeed Jae in the position of chief investment officer (CIO) at the time of Jae’s retirement. Jae and David have partnered in their oversight of Loomis Sayles’ investment platforms and infrastructure since David was named Loomis Sayles’ first deputy CIO in 2013.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005226/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Loomis Sayles Chief Investment Officer Jae Park set to retire in 2021. (Photo: Business Wire)

“David is the ideal successor to Jae; they have been longtime partners responsible for overseeing Loomis Sayles’ investment and research teams and David has been instrumental in building key components of the firm’s investment infrastructure over the past 13 years,” said Kevin Charleston, chairman and chief executive officer of Loomis Sayles. “David has dedicated his career to investment excellence and will continue to lead our ongoing efforts to refine our investment processes and promote rigor, repeatability and discipline. We are confident that David’s continued leadership will carry Loomis Sayles into its next phase of global growth and success.”

As CIO, David will assume leadership responsibilities for all Loomis Sayles investment, research, and trading teams with the exception of the Growth Equity Strategies (GES) team. GES is led by Aziz Hamzaogullari, EVP and founder, CIO and portfolio manager of the Growth Equity Strategies team. He will report directly to Kevin Charleston.

Jae joined Loomis Sayles in 2002 after 21 years with IBM, where he served as director of fixed income investments for the firm’s retirement fund. During his tenure at IBM, Jae vetted a wide range of investment management teams and developed a strong view of the key attributes of a successful investment process. Jae has applied that view to Loomis Sayles’ investment teams, their processes and the supporting research infrastructure since joining the firm.

“Jae’s vision for Loomis Sayles and the foundations he put in place have led to tremendous firm-wide growth, product expansion and a global reputation for investment excellence. During his tenure, assets under management have grown from $54 billion to our current all-time high of $328 billion,” said Kevin Charleston. “We are all grateful to Jae for his commitment and contributions to Loomis Sayles and our clients, and wish him the best in his next chapter.”

David joined Loomis Sayles in 2007 as director of quantitative research and risk analysis. He was promoted to deputy CIO in 2013, a position established in part to provide a succession plan for Jae. In 2015, David was appointed to the Loomis Sayles board of directors. Over the last seven years, Jae has systematically passed increasing oversight responsibilities to David across investments, research and trading. Notably, David assumed responsibility for Macro Strategies and Credit Research in 2015, oversight of Trading in 2018 and established the Custom Income Strategies team in 2019.

ABOUT LOOMIS SAYLES

Since 1926, Loomis, Sayles & Company has helped fulfill the investment needs of institutional and mutual fund clients worldwide. The firm’s performance-driven investors integrate deep proprietary research and integrated risk analysis to make informed, judicious decisions. Teams of portfolio managers, strategists, research analysts and traders collaborate to assess market sectors and identify investment opportunities wherever they may lie, within traditional asset classes or among a range of alternative investments. Loomis Sayles has the resources, foresight and the flexibility to look far and wide for value in broad and narrow markets in its commitment to deliver attractive sustainable returns for clients. This rich tradition has earned Loomis Sayles the trust and respect of clients worldwide, for whom it manages $328 billion ** in assets (as of September 30, 2020).

**Includes the assets of Loomis, Sayles & Co., LP, and Loomis Sayles Trust Company, LLC. Loomis Sayles Trust Company is a wholly owned subsidiary of Loomis, Sayles & Company, LP.

ABOUT NATIXIS INVESTMENT MANAGERS

Natixis Investment Managers serves financial professionals with more insightful ways to construct portfolios. Powered by the expertise of more than 20 specialized investment managers globally, we apply Active Thinking® to deliver proactive solutions that help clients pursue better outcomes in all markets. Natixis Investment Managers ranks among the world’s largest asset management firms 1 with $908.9 billion / €828.4 billion assets under management. 2

Natixis Investment Managers includes all of the investment management and distribution entities affiliated with Natixis Distribution, L.P. and Natixis Investment Managers S.A. Services/ products are not available to all investors in all jurisdictions.

1Cerulli Quantitative Update: Global Markets 2019 ranked Natixis Investment Managers as the 17th largest asset manager in the world based on assets under management as of December 31, 2018.
2 Assets under management (“AUM”) as of March 31, 2020. AUM, as reported, may include notional assets, assets serviced, gross assets, assets of minority-owned affiliated entities and other types of non-regulatory AUM managed or serviced by firms affiliated with Natixis Investment Managers.

Natixis Distribution L.P. (fund distributor FINRA|SIPC) and Loomis, Sayles & Company, L.P. are affiliated.

MALR026188

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Orla O’Brien
+1(617)478-7480
oobrien@loomissayles.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye